Financial Performance: Narrowed Loss and Strengthened Cash Position GRI Bio recently released its financial report for the first quarter of 2026. The data shows the company reported a net loss of approximately $2 million for the quarter, a significant improvement from the $3 million loss in the same period last year. Research and development expenses were $400,000, a substantial decrease from $1.6 million in the prior-year period, primarily due to the completion of the Phase 2a clinical trial for GRI-0621 in 2025. As of March 31, 2026, the company's cash and cash equivalents were approximately $11 million, up from $8.2 million at the end of 2025. The company raised gross proceeds of about $6.8 million through an at-the-market equity offering program. The current funds are expected to support operations into the second quarter of 2027.
Core Pipeline: GRI-0621 Demonstrates Differentiated Advantages Dr. Marc Hertz, Chief Executive Officer of the company, stated that additional analyses from the Phase 2a clinical trial continue to validate the differentiated therapeutic potential of GRI-0621 in idiopathic pulmonary fibrosis. Data indicates that, on top of standard antifibrotic therapy, the active treatment group achieved zero cough, a 76% reduction in dyspnea, and no weight loss, with treatment-related diarrhea reduced by approximately 60% compared to the placebo group. No serious adverse events were reported in the active group. Furthermore, exploratory lung function analysis showed an overall improvement in forced vital capacity of 99 mL in the patient population, with a 139 mL improvement in the subgroup receiving combination standard therapy, outperforming the placebo plus standard therapy group.
Pipeline Progress and Strategic Plans The company is advancing the clinical development plan for GRI-0621 to support potential regulatory pathways in the United States and Europe, while also progressing its autoimmune disease candidate, GRI-0803, toward an Investigational New Drug application. Based on the positive data, the company has submitted additional patent applications.
Comments